Summary of AngioDynamics, Inc.

Business Overview

• Type of Company: Medical technology company focused on innovative devices for cardiovascular disease and cancer treatment.
• Core Mission: Expand treatment options, improve patient outcomes, and enhance quality of life through the design, manufacturing, and sale of medical devices.

History & Operations

• Founded in 1988 in Queensbury, NY.
• Headquartered in Latham, NY.
• Manufacturing facilities mainly located in Queensbury, NY; also operates in Glens Falls, NY, and internationally.
• Publicly traded on NASDAQ under the ticker ANGO.

Products & Segments

Main Segments:

• Med Tech:
  • Products include atherectomy systems (e.g., Auryon), thrombus management platforms (AngioVac, AlphaVac, Uni-Fuse), NanoKnife (IRE ablation system), and peripheral products like angiographic catheters, guidewires, drainage catheters, micropuncture kits, ports, and venous insufficiency devices.
  • Focus on minimally invasive, image-guided procedures for cardiovascular and oncological applications.
  • Designed for both short-term and long-term use, often single-use or temporary implants.
• Med Device:
  • Products include vascular access devices (PICC, Midline catheters, ports), vascular and oncological interventional devices, microwave tissue ablation systems (Solero), and specialized balloons (IsoLoc, Alatus).

Key Product Highlights:

• Auryon Atherectomy System: For peripheral arterial disease; employs optimized wavelength and pulse technology with integrated aspiration.
• Thrombus Management Portfolio: Includes AlphaVac, AngioVac, and catheter-based thrombolytic delivery systems.
• NanoKnife IRE System: Non-thermal soft tissue ablation; expanded in 2024 for prostate tissue.
• Venous Disease: VenaCure EVLT laser system for varicose veins; uses microwave ablation technology.
• Other Devices: VenaCure EVLT, microwave applicators, balloons, ports, guidewires, drainage catheters.

Business Strategy & R&D

• Focused on innovative R&D, expanding clinical, regulatory pathways, and customer-centric sales.
• Investments in products like Auryon, NanoKnife, Thrombus Management, and AlphaVac.
• Engages in clinical trials (e.g., RECOVER-AV, AMBITION BTK).
• Invests in streamlining manufacturing and global expansion, maintaining a presence in certain U.S. locations while outsourcing others.

Customers & Markets

• Customer Base: Interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, critical care nurses.
• Sales Channels: Primarily through a direct sales force in the U.S.; international sales via distributor relationships.
• International Operations: Heavy dependence on third-party distributors outside North America (~74% of international sales in FY2025).
• Number of Employees: Approximately 675 full-time employees as of May 31, 2025.
• Revenue (FY2025): Approximately $292.5 million (a 3.8% decrease from FY2024).
• Income: Reported a net loss of $34.0 million in FY2025, compared to a net loss of $184.3 million in FY2024.
• Market Capitalization: As of November 30, 2024, was approximately $245 million.
• Shares Outstanding: 40,633,885 shares as of July 16, 2025.

Key Corporate and Financial Strategies

• Asset divestitures (e.g., PICC/Midline, dialysis, BioSentry) to optimize operations.
• Share repurchase program initiated in 2024 with a $15 million authorization.
• Debt facilities arranged, including a $25 million revolving credit line (no current debt as of May 31, 2025).
• Cost-saving initiatives under way, expected to generate $15 million yearly savings starting FY2027.

Summary

AngioDynamics is a global provider of minimally invasive medical devices targeting cardiovascular disease and oncology. Its innovations focus on advanced atherectomy, thrombus management, tissue ablation, and vascular access products. The company employs around 675 employees, generated $292.5 million in FY2025 revenue, and reported a net loss of $34 million. It emphasizes R&D, clinical trials, and strategic realignments, including manufacturing streamlining and divestitures, to drive future growth.